Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Salarius Pharmaceuticals Inc SLRX

Healthcare Biotechnology
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SLRX)

Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting

GlobeNewswire June 17, 2024

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

GlobeNewswire June 12, 2024

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 22, 2024

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

GlobeNewswire February 22, 2024

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

GlobeNewswire January 16, 2024

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

GlobeNewswire January 3, 2024

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

GlobeNewswire November 7, 2023

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

GlobeNewswire August 10, 2023

Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources

GlobeNewswire August 8, 2023
View More News ››

Opinion & Analysis (NDAQ:SLRX)

Seven biotech names on the upswing: 2016 small-cap biotech watchlist update

The Life Sciences Report March 11, 2016
View More Opinion ››

Bullboard Posts (NDAQ:SLRX)

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX): Exploring Stra

http://beyondspx.com/2024/08/02/salarius-pharmaceuticals-inc-nasdaqslrx-exploring-strategic-alternatives-amidst-challenging-financials/
MikeTester - August 3, 2024

FLKS .64~NASDAQ~HUGE MERGER VOTE TODAY! $3-$5 PT

FLKS LAST DAY FOR MERGER VOTE IS TODAY!!!! This is most likely going to go through with the MERGER.  FLKS has huge upside potential...
BerkshireCapGrp - June 14, 2019

breakout alert for this morning

lots of action for today,so glta shareholders like me.
coolfooldumbguy - April 15, 2019

buying this stock big time today

at 55cents per share,it was a bargain for me and who doesn't like bargains,so glta.
coolfooldumbguy - January 4, 2019

Volatility

FLKS has been popping up and down like a string of Chisese firecrackers. Does anyone know the reasons for this?  This seemed more...
EdinColorado - April 27, 2015
View more Bullboard ››

Tidal Care Inc.

Tidal Care Inc.

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the ...
View More »